Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMUX |
---|---|---|
09:32 ET | 16582 | 1.19 |
09:33 ET | 38730 | 1.175 |
09:35 ET | 900 | 1.1796 |
09:37 ET | 1159 | 1.173 |
09:39 ET | 12401 | 1.165 |
09:42 ET | 7059 | 1.165 |
09:44 ET | 10148 | 1.16 |
09:46 ET | 1129 | 1.155 |
09:48 ET | 6968 | 1.17 |
09:50 ET | 4348 | 1.165 |
09:51 ET | 200 | 1.165 |
09:53 ET | 611 | 1.1647 |
09:55 ET | 2261 | 1.165 |
09:57 ET | 2624 | 1.165 |
10:00 ET | 100 | 1.165 |
10:02 ET | 9215 | 1.165 |
10:04 ET | 2824 | 1.165 |
10:06 ET | 100 | 1.165 |
10:08 ET | 100 | 1.16 |
10:09 ET | 1300 | 1.1606 |
10:11 ET | 809 | 1.165 |
10:13 ET | 1000 | 1.165 |
10:15 ET | 5005 | 1.155 |
10:18 ET | 700 | 1.1533 |
10:20 ET | 503 | 1.15 |
10:22 ET | 1564 | 1.1512 |
10:24 ET | 726 | 1.155 |
10:26 ET | 22334 | 1.1606 |
10:27 ET | 1600 | 1.16 |
10:29 ET | 1279 | 1.155 |
10:31 ET | 1355 | 1.1508 |
10:33 ET | 5549 | 1.15 |
10:36 ET | 8406 | 1.155 |
10:38 ET | 594 | 1.1586 |
10:40 ET | 200 | 1.15 |
10:42 ET | 3373 | 1.15 |
10:44 ET | 2100 | 1.15 |
10:45 ET | 1783 | 1.155 |
10:47 ET | 907 | 1.151 |
10:51 ET | 10961 | 1.155 |
10:54 ET | 600 | 1.155 |
10:56 ET | 918 | 1.15 |
10:58 ET | 685 | 1.15 |
11:00 ET | 5318 | 1.15 |
11:02 ET | 8313 | 1.15 |
11:03 ET | 100 | 1.155 |
11:05 ET | 837 | 1.155 |
11:07 ET | 200 | 1.155 |
11:12 ET | 1878 | 1.15 |
11:14 ET | 7416 | 1.15 |
11:16 ET | 1768 | 1.15 |
11:18 ET | 2422 | 1.15 |
11:20 ET | 200 | 1.1559 |
11:21 ET | 853 | 1.155 |
11:23 ET | 731 | 1.1512 |
11:25 ET | 400 | 1.15 |
11:27 ET | 252 | 1.15 |
11:30 ET | 305 | 1.15 |
11:32 ET | 557 | 1.155 |
11:34 ET | 1200 | 1.155 |
11:36 ET | 1100 | 1.15 |
11:38 ET | 453 | 1.15 |
11:39 ET | 100 | 1.155 |
11:41 ET | 424 | 1.15 |
11:43 ET | 860 | 1.15 |
11:45 ET | 100 | 1.1591 |
11:48 ET | 10529 | 1.16 |
11:50 ET | 100 | 1.17 |
11:52 ET | 9876 | 1.165 |
11:54 ET | 2332 | 1.16 |
11:56 ET | 899 | 1.16 |
11:59 ET | 600 | 1.165 |
12:01 ET | 500 | 1.165 |
12:03 ET | 220 | 1.164 |
12:06 ET | 100 | 1.165 |
12:08 ET | 544 | 1.16 |
12:10 ET | 227 | 1.165 |
12:12 ET | 2719 | 1.165 |
12:14 ET | 1232 | 1.1696 |
12:15 ET | 2755 | 1.175 |
12:19 ET | 100 | 1.175 |
12:21 ET | 1900 | 1.175 |
12:24 ET | 100 | 1.175 |
12:26 ET | 100 | 1.175 |
12:30 ET | 1724 | 1.185 |
12:32 ET | 27504 | 1.18 |
12:33 ET | 1300 | 1.185 |
12:35 ET | 200 | 1.185 |
12:37 ET | 100 | 1.1896 |
12:39 ET | 300 | 1.185 |
12:42 ET | 1250 | 1.1804 |
12:44 ET | 100 | 1.18 |
12:46 ET | 693 | 1.18 |
12:48 ET | 2300 | 1.18 |
12:50 ET | 10509 | 1.175 |
12:51 ET | 4391 | 1.175 |
12:53 ET | 9400 | 1.16 |
12:55 ET | 928 | 1.165 |
12:57 ET | 700 | 1.1699 |
01:00 ET | 653 | 1.165 |
01:02 ET | 550 | 1.16 |
01:04 ET | 5002 | 1.16 |
01:06 ET | 100 | 1.165 |
01:08 ET | 44242 | 1.16 |
01:09 ET | 1000 | 1.16 |
01:11 ET | 1300 | 1.165 |
01:13 ET | 400 | 1.16 |
01:15 ET | 18344 | 1.155 |
01:18 ET | 818 | 1.155 |
01:20 ET | 900 | 1.155 |
01:22 ET | 6221 | 1.1591 |
01:24 ET | 4325 | 1.155 |
01:27 ET | 2400 | 1.155 |
01:29 ET | 634 | 1.155 |
01:31 ET | 100 | 1.155 |
01:33 ET | 782 | 1.155 |
01:36 ET | 908 | 1.155 |
01:38 ET | 300 | 1.16 |
01:40 ET | 1350 | 1.155 |
01:42 ET | 1000 | 1.15 |
01:44 ET | 400 | 1.155 |
01:45 ET | 800 | 1.155 |
01:47 ET | 400 | 1.155 |
01:49 ET | 200 | 1.155 |
01:51 ET | 1329 | 1.15 |
01:54 ET | 1647 | 1.16 |
01:56 ET | 100 | 1.155 |
01:58 ET | 600 | 1.15 |
02:00 ET | 926 | 1.15 |
02:02 ET | 100 | 1.15 |
02:03 ET | 200 | 1.155 |
02:05 ET | 722 | 1.15 |
02:07 ET | 100 | 1.155 |
02:09 ET | 619 | 1.15 |
02:12 ET | 200 | 1.155 |
02:14 ET | 1992 | 1.155 |
02:16 ET | 1095 | 1.15 |
02:18 ET | 1000 | 1.15 |
02:20 ET | 366 | 1.15 |
02:21 ET | 800 | 1.16 |
02:23 ET | 800 | 1.15 |
02:25 ET | 8550 | 1.1599 |
02:27 ET | 200 | 1.155 |
02:30 ET | 1013 | 1.15 |
02:32 ET | 100 | 1.155 |
02:34 ET | 200 | 1.15 |
02:36 ET | 695 | 1.155 |
02:38 ET | 864 | 1.15 |
02:39 ET | 3018 | 1.15 |
02:41 ET | 100 | 1.15 |
02:43 ET | 44160 | 1.14 |
02:48 ET | 1238 | 1.14 |
02:50 ET | 100 | 1.14 |
02:52 ET | 4775 | 1.14 |
02:54 ET | 2300 | 1.14 |
02:56 ET | 1700 | 1.14 |
02:57 ET | 4773 | 1.13 |
02:59 ET | 3375 | 1.13 |
03:01 ET | 2204 | 1.1304 |
03:03 ET | 712 | 1.13 |
03:06 ET | 10799 | 1.13 |
03:08 ET | 1024 | 1.13 |
03:10 ET | 504 | 1.13 |
03:12 ET | 474 | 1.1347 |
03:14 ET | 3502 | 1.1383 |
03:15 ET | 2100 | 1.13 |
03:17 ET | 300 | 1.13 |
03:19 ET | 996 | 1.13 |
03:21 ET | 100 | 1.135 |
03:24 ET | 400 | 1.135 |
03:26 ET | 2797 | 1.1356 |
03:28 ET | 200 | 1.13 |
03:30 ET | 300 | 1.13 |
03:32 ET | 515 | 1.13 |
03:33 ET | 200 | 1.135 |
03:35 ET | 535 | 1.13 |
03:37 ET | 200 | 1.13 |
03:39 ET | 733 | 1.13 |
03:42 ET | 100 | 1.13 |
03:44 ET | 1252 | 1.135 |
03:46 ET | 2488 | 1.135 |
03:48 ET | 2333 | 1.135 |
03:50 ET | 921 | 1.13 |
03:51 ET | 15714 | 1.1394 |
03:53 ET | 4986 | 1.145 |
03:55 ET | 5480 | 1.14 |
03:57 ET | 1043 | 1.14 |
04:00 ET | 25004 | 1.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunic Inc | 99.1M | -0.9x | --- |
Nuvectis Pharma Inc | 98.5M | -4.4x | --- |
Leap Therapeutics Inc | 97.7M | -1.4x | --- |
Fractyl Health Inc | 100.5M | -1.5x | --- |
Regulus Therapeutics Inc | 96.3M | -1.4x | --- |
Anixa Biosciences Inc | 103.0M | -8.5x | --- |
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $99.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 90.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.89 |
EPS | $-1.24 |
Book Value | $0.64 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.